Analyst Soumit Roy from JonesTrading maintained a Buy rating on aTyr Pharma (ATYR – Research Report) and keeping the price target at $22.00.
Soumit Roy’s rating is based on several compelling factors that suggest aTyr Pharma’s stock is an attractive investment opportunity. The recent pullback in the stock, in line with the broader market, is seen as a chance to buy, especially given the positive momentum from Phase 2 data and the absence of significant competitive pressure. The company’s valuation model indicates the potential for substantial stock appreciation, particularly if Phase 3 data is favorable, with expectations of a 30-40% rally in the coming months if market conditions stabilize.
Additionally, the continuation of the Phase 3 EFZO-FIT trial without modifications, as recommended by the independent DSMB, underscores the drug’s favorable safety profile. This milestone is significant as it suggests efzofitimod could be a viable option for chronic and maintenance therapy. The trial’s design, aiming to demonstrate a reduction in steroid dosage, along with promising results from earlier trials showing improvements in lung function and quality of life, further supports the Buy rating. The upcoming Phase 3 data, expected in the third quarter of 2025, is highly anticipated and could be a major catalyst for the stock.
In another report released today, Piper Sandler also maintained a Buy rating on the stock with a $20.00 price target.
Questions or Comments about the article? Write to editor@tipranks.com